1. Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome
- Author
-
Robert A. Fowler, Yaseen M. Arabi, Patrick J. Lindsay, Maria D. Van Kerkhove, Neill K. J. Adhikari, and Taylor Kain
- Subjects
Epidemiology ,medicine.medical_treatment ,coronavirus ,lcsh:Medicine ,medicine.disease_cause ,corticosteroids ,chemistry.chemical_compound ,antivirals ,0302 clinical medicine ,systematic review ,intravenous immunoglobulin ,030212 general & internal medicine ,Middle East respiratory syndrome ,Mortality rate ,interferon ,Infectious Diseases ,convalescent plasma ,Middle East Respiratory Syndrome Coronavirus ,Synopsis ,Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome ,Microbiology (medical) ,medicine.medical_specialty ,ribavirin ,Middle East respiratory syndrome coronavirus ,CoV ,030231 tropical medicine ,severe acute respiratory syndrome ,Antiviral Agents ,lcsh:Infectious and parasitic diseases ,respiratory infections ,03 medical and health sciences ,coronavirus infections ,MERS ,medicine ,Extracorporeal membrane oxygenation ,Humans ,lcsh:RC109-216 ,viruses ,Intensive care medicine ,business.industry ,Ribavirin ,lcsh:R ,acute respiratory distress syndrome ,medicine.disease ,zoonoses ,supportive care ,Clinical trial ,chemistry ,Observational study ,Treatment decision making ,business - Abstract
Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). We conducted a systematic review of evidence for treatment with pharmacologic and supportive therapies. We developed a protocol and searched 5 databases for studies describing treatment of MERS and deaths in MERS patients. Risk of bias (RoB) was assessed by using ROBINS-I tool. We retrieved 3,660 unique citations; 20 observational studies met eligibility, and we studied 13 therapies. Most studies were at serious or critical RoB; no studies were at low RoB. One study, at moderate RoB, showed reduced mortality rates in severe MERS patients with extracorporeal membrane oxygenation; no other studies showed a significant lifesaving benefit to any treatment. The existing literature on treatments for MERS is observational and at moderate to critical RoB. Clinical trials are needed to guide treatment decisions.
- Published
- 2020
- Full Text
- View/download PDF